Archive
Arcontech slumps as customers reduce spend
A look at some of the major movers in London on Monday
Company
Avacta Group PLC
LON:AVCT
At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets. Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.
207 stories · page 2 of 11
Avacta starts shipment of new rapid COVID-19 test
The assay has been shown by independent clinical evaluation to be 100% sensitive for patient samples with a high viral load
Archive
Record on the right track with UBS partnership
A look at the major movers on the London market on Tuesday
A year of COVID-19: the healthcare industry
It’s been a year since the UK had to revolutionise its way of life to cope with the pandemic, while the healthcare sector has been at the forefront of it all
Avacta notes press speculation on UK Government take-up of rapid COVID-19 test
It is understood that the Avacta rapid kits could play a key part in the so-called ‘Operation Moonshot’ to reopen public places such as theatres, clubs and cinemas
Avacta, Clipper, Eurasia Mining and Persimmon in broker's new 'climate portfolio'
The initial portfolio is made up of 20 stocks, ranging from three from the FTSE 100 to more than half a dozen from AIM
Pharma learns many lessons from COVID-19 shockwave
2020 has been a transformative year for the industry
Avacta to launch affimer-based laboratory test for COVID-19
The assay uses enzyme-linked immunosorbent assays (ELISAs) and Avacta's engineered proteins Affimers
Avacta Group: Liverpool School of Tropical Medicine to validate rapid coronavirus test
Scientists will evaluate the performance of a diagnostic test using real patient samples
Avacta tackles the pandemic on all fronts with its Affimer technology
The biotech is using its engineered proteins to develop diagnostics and treatment for Covid-19
Coronavirus: UK to trial saliva tests for asymptomatic cases, Evan Bioscences’ candidate enters Cambridge trial, R factor rises in Germany…
A look at Monday's major developments regarding coronavirus spread, testing and treatment
Archive
Proactive news snapshot: Avacta, Itaconix, SDX Energy, Premier African Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
Avacta "highly encouraged" by early results from dual threat cancer drug
The new technology outperformed Bavencio, a PD-L1 antibody inhibitor for lung cancer sold by Merck and Pfizer
Archive
Small Cap Wrap - Gear4music, Avacta Group, ITM Power and more...
Dish of the day No Joiners Today Off the menu No Leavers Today What’s cooking in the IPO kitchen?
Archive
Proactive news snapshot: Avacta Group, Diversified Gas & Oil, Summit Therapeutics PLC, Arix Bioscience …
A glance at some of the day's highlights from the Proactive Investors newswire
Avacta's revenues and cash ahead of expectation as it prepares to take its first drug candidate into the clinic
The company is the developer of antibody-like proteins called Affimers
Archive
CLS Holdings dips over acquisition, sale
A look at the day's major movers in the London Stock Exchange
Avacta creates cell therapy JV with Korea's Daewoong Pharmaceutical
The new joint venture with Daewoong Pharmaceutical will target development of a new class of stem cells that are primed to produce Affimer proteins against several undisclosed targets
Avacta says expanded LG Chem collaboration could trigger further "substantial" payments
The company is a specialist in developing Affimers, which are engineered proteins that help drugs more effectively target diseases such as cancer
Avacta raises £9mln as its moves towards first clinical trial
Seven evaluations are ongoing with possible partners, which includes four out of the top ten global diagnostics companies.